Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYuntong LiuSDShuhui DengLQLugui Qiu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows safety and efficacy of ixazomib transition in transplant-ineligible patients with multiple myeloma, implying better treatment convenience.

Key Points

  • This study evaluates the efficacy and safety of transitioning from bortezomib to ixazomib-based regimens in transplant-ineligible patients with NDMM.
  • Single-center, non-interventional, retrospective analysis
  • Included adult patients with transplant-ineligible NDMM
  • Analyzed data from the NICHE-MM registry
  • Primary endpoint: overall response rate (ORR); secondary endpoints: progression-free survival (PFS), overall survival (OS)
  • 107 patients transitioned from bortezomib to ixazomib-based regimens
  • ORR after transition was 79% with 68% achieving a very good partial response or better
  • Median PFS was 38.0 months with a 12-month PFS rate of 80%
  • Median OS not reached, with a 12-month OS rate of 92%
  • Safety profile of ixazomib consistent with previous trials

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2afhttps://doi.org/10.1182/blood-2025-7550
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China2025
  2. 2Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  3. 3Assessment of prolonged proteasome inhibition through <scp>ixazomib‐based</scp> oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A <scp>real‐world</scp> Chinese cohort study2024 · 4 citations
  4. 4Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma2025
  5. 5Enhancing Multiple Myeloma Treatment Outcomes with Ixazomib: Insights and Perspectives2024